The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐FU in pancreatic cancer

Documenti analoghi

• Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis
  di: Hayato Kawamura, et al.
  Pubblicazione: (2025)
• DPYD and fluoropyrimidines: Using the data as our guide
  di: Christine M. Walko
  Pubblicazione: (2024)
• Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance
  di: Taku Naiki, et al.
  Pubblicazione: (2025)
• Response to “DPYD genotyping panels: Impact of population diversity”
  di: Andrea Gaedigk, et al.
  Pubblicazione: (2024)
• Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing
  di: Sofía L. J. Peeters, et al.
  Pubblicazione: (2025)